Актуальность и методы коррекции вторичной гипогаммаглобулинемии в клинической практике

摘要: Advance protocols for the treatment most of oncology, hematology and some inherited disorders may lead to development severe secondary hypogammaglobulinaemia. Particularly, it is often caused by therapy with monoclonal antibodies binding B-cells (such as rituximab, belimumab, inotuzumab), inhibitors tyrosine-kinase (imatinib, desatinib), well applying a variety immunosuppressive chemotherapy agents (steroids, azathioprine, cyclophosphamide etc.). It should be note, that chronic lymphoid leukemia multiple myeloma could complicated hypogammaglobulinaemia, not only because specific therapy, but also features diseases. Hematopoietic stems cells transplantation can prolonged This associated intensive immune/myeloablative immunologic reconstitution after transplantation. Modern intravenous immunoglobulins (IVIG) have wide repertoire pathogen-specific activity high safety profile constitute essential part patients The paper presents literature review IVIG usage in various clinical situations, several examples personal experience.